EAU UroEvidenceHub launches prospective Prostate Cancer Data Registry with first patient successfully ddded
The EAU UroEvidence Hub (UEH) is proud to announce the launch of its groundbreaking Prostate Cancer Data Registry - ProReg, a state-of-the-art platform designed to collect, manage, and analyse critical data to advance research and treatment for prostate cancer. This milestone event is marked by the successful enrolment of the registry's first patient, signifying a major step forward in the fight against prostate cancer.
ProReg aims to serve as a comprehensive resource for researchers, healthcare providers, and patients by compiling high-quality, pseudo-anonymised data that spans the entire patient journey from diagnosis to treatment outcomes. By leveraging this information, the registry seeks to enhance clinical decision-making, enable personalised medicine and foster the development of new therapeutic approaches to improve patient outcomes.
“This is an important day for our organisation and the prostate cancer community,” said Prof. Philip Cornford, Chair of the UEH. “With the enrolment of our first patient, we are laying the foundation for a data-driven future in prostate cancer care. This registry is not only a tool for scientific advancement but also a testament to the power of collaboration between patients, clinicians, and researchers.”
ProReg was developed with input from leading oncologists, data scientists, and patient advocates to ensure its design reflects the needs and priorities of all stakeholders. The registry is built to accommodate a broad spectrum of data, including:
- Clinical data: Information on diagnosis, staging, and treatment modalities.
- Patient-reported outcomes: Insights into the quality of life, symptoms, and overall patient experience.
- Genomic and biomarker data: Cutting-edge data to drive personalised medicine and targeted therapies.
- Participation in the registry is voluntary and fully compliant with data privacy regulations, ensuring that patient confidentiality and data security remain paramount.
Prostate cancer remains one of the most common cancers among men, affecting millions worldwide. By collecting and analysing real-world data, ProReg aims to fill critical knowledge gaps, facilitate early detection strategies, and support the development of more effective personalised treatments.
“This initiative represents hope for the millions of individuals and families affected by prostate cancer,” said Dr. Erik Briers, UEH Board Member and Patient Advocate, involved in the registry's launch. “With every patient who joins, we gain new insights that bring us closer to tailor made treatments for individual patients.”
The addition of the first patient marks the beginning of a long-term commitment to building a robust and impactful data repository. UEH invites healthcare providers, researchers, and patient organisations to collaborate in this vital effort.
For more information about the ProReg and how to participate, please visit its website or contact Emma Jane Smith.
EAU UroEvidenceHub is dedicated to advancing the understanding, treatment, and prevention of urological conditions through innovative research, patient-centred care, and strategic partnerships.
Media Contact: Jarka Bloemberg